PerCP anti-mouse CD4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

BALB/c mouse thymocytes

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with PerCP under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP has a maximum absorption of 482 nm and a maximum emission of 675 nm.

Excitation Laser

Blue Laser (488 nm)

Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4⁺ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4⁺ cells¹, and immunohistochemistry of acetone-fixed frozen tissue sections^2,3,11 and paraffin-embedded sections¹¹. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)

1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)

Product Citations

1. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
2. Yang R, et al. 2020. Cell Death Dis. 0.877083333. PubMed
3. Rezende R, et al. 2015. Nat Commun. 6: 8726. PubMed
4. Martens R, et al. 2020. Nat Commun. 11:1114. PubMed
5. Swadling L, et al. 2020. Cell Rep. 30:687. PubMed
6. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
7. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
8. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
9. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
10. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
11. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
12. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
13. Roy S, et al. 2020. Sci Rep. 10:10992. PubMed
14. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
15. Shrivastava T, et al. 2021. Front Immunol. 12:641447. PubMed
16. Thauland T, et al. 2014. J Immunol. 193:5894. PubMed
17. Köchl R, et al. 2020. Elife. 9:00. PubMed
18. Xu L et al. 2017. Immunity. 47(3):538-551 . PubMed
19. Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed
20. Knizkova D, et al. 2022. Nat Immunol. 23:1644. PubMed
21. Jacque E, et al. 2015. J Exp Med. 212:883. PubMed
22. Schuldt N, et al. 2015. PLoS One. 10: 0145762. PubMed
23. Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed
24. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
25. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
26. Robles-Oteiza C, et al. 2021. Dis Model Mech. 14:. PubMed
27. Derada Troletti C, et al. 2021. Cell Reports. 35(9):109201. PubMed
28. Riva A, et al. 2017. PLoS One.. 10.1371/journal.pone.0181964. PubMed
29. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
30. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
31. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
32. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
33. Menon M, et al. 2014. PLoS Genet. 10:1004558. PubMed
34. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
35. Jacque E, et al. 2014. J Exp Med. 211:2085. PubMed
36. Tao Z, et al. 2022. Cells. 11:. PubMed
37. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
38. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
39. Tang L, et al. 2022. Front Immunol. 12:770402. PubMed
40. Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed
41. Ito Y, et al. 2021. Cell Reports. 35(4):109052. PubMed
42. Yuan M, et al. 2017. Hum Reprod. 32:94. PubMed
43. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed

RRID

AB_893331 (BioLegend Cat. No. 100537)
AB_893325 (BioLegend Cat. No. 100538)

Antigen Details

Structure

Ig superfamily, 55 kD

Distribution

Majority of thymocytes, T cell subset

Function

TCR co-receptor, T cell activation

Ligand/Receptor

MHC class II molecule

Cell Type

Dendritic cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID

12504 View all products for this Gene ID

UniProt

View information about CD4 on UniProt.org

Documentation

• Technical data sheet
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

How stable is PerCP/Cy5.5 tandem as compared to PerCP alone?

PerCP/Cy5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.

TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

Concentration & Expiration Lookup

Certificate of Analysis